Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Yukihiko, Tokunaga"'
Autor:
Hisato Kawakami, Naotoshi Sugimoto, Takeshi Kato, Taroh Satoh, Masaki Tsujie, Shu Okamura, Yukihiko Tokunaga, Shigeyoshi Iwamoto, Takashi Ohta, Masato Nakamura, Masahito Kotaka, Taishi Hata, Toshio Shimokawa, Hideyuki Mishima, Yukinori Kurokawa, Yasuhiro Miyake, Toshio Otsuji, Masahiro Goto
Publikováno v:
International Journal of Clinical Oncology. 25:1291-1298
Older or frail patients are often underrepresented in clinical trials for metastatic colorectal cancer (mCRC). We here assessed the efficacy and safety of 5-fluorouracil (5-FU)–leucovorin plus bevacizumab in such patients. The study (OGSG 0802) was
Autor:
Sadayuki Doi, Naohiro Tomita, Hidetoshi Fujiwara, Ryuichi Mikami, Yoshihiko Nakamoto, Masafumi Noda, Tatsuo Okumoto, Takashi Kawamura, Yukihiko Tokunaga
Publikováno v:
International Journal of Clinical Oncology. 25:1285-1290
Fluorouracil and leucovorin combined with oxaliplatin or irinotecan plus bevacizumab (Bmab) or cetuximab (Cmab) are now widely accepted treatment options as first-line or second-line chemotherapy for metastatic colorectal cancer (mCRC). Sequential ch
Autor:
Hiroyuki, Kodama, Motoki, Yoshida, Masahiro, Goto, Masato, Nakamura, Hiroko, Hasegawa, Atsushi, IKeda, Yukihiko, Tokunaga, Kazufumi, Tanigawa, Tetsuji, Terazawa, Daisuke, Sakai, Yukinori, Kurokawa, Hisato, Kawakami, Toshio, Shimokawa, Taroh, Satoh
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 48(10)
Regorafenib(Rego)is the salvage line standard treatment for metastatic colorectal cancer(mCRC), which often causes severe toxicities, such as hand-foot syndrome. Previously, we reported that in phase Ⅱ study, S-1 plus bevacizumab( Bev)(SB)showed fa
Autor:
Masato Kataoka, Mitsuro Kanda, Tadamichi Denda, Koji Oba, Naoki Nagata, Yoshinori Munemoto, Junichi Sakamoto, Hiroyoshi Takemoto, Hideyuki Mishima, Yukihiko Tokunaga, Ho Min Kim, Mutsumi Fukunaga, Nao Takano
Publikováno v:
Cancer Chemotherapy and Pharmacology. 81:829-838
Fluorouracil monotherapy, instead of the FOLFOX or FOLFIRI regimen, is administered to patients intolerant to oxaliplatin or irinotecan because of their adverse effects. A prospective clinical trial was designed to evaluate the efficacy and safety of
Autor:
Hirokazu Sasaki, Yukihiko Tokunaga
Publikováno v:
Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons). 41:143-146
Autor:
Michitaka Honda, Ho Min Kim, Chihiro Kosugi, Hideyuki Mishima, Hiroyoshi Takemoto, Yukihiko Tokunaga, Junichi Sakamoto, Ken Kondo, Koji Oba, Chihiro Tanaka, Takao Takahashi, Chu Matsuda
Publikováno v:
Cancer chemotherapy and pharmacology. 81(6)
The aim of this single-arm phase II clinical trial was to evaluate whether the alternate-day administration of S-1 plus irinotecan would reduce the incidence of severe diarrhea in comparison to consecutive-day S-1 administration (standard IRIS regime
Autor:
Yukihiko Tokunaga, Hirokazu Sasaki
Publikováno v:
International Surgery. 100:974-978
A variety of techniques have been described to treat complex anal fistulas. When complex anal fistulas are associated with hidradenitis suppurativa, the treatment has to be appropriately tailored for the severity and distribution of the disease so as
Autor:
Yukihiko Tokunaga, Hirokazu Sasaki
Publikováno v:
Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons). 40:651-655
Autor:
Yukihiko Tokunaga
Publikováno v:
Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons). 39:861-864
Autor:
Koji Oba, C. Tanaka, Takao Takahashi, Chihiro Kosugi, H. Takemoto, Yukihiko Tokunaga, Hideyuki Mishima, Ken Kondo, H.M. Kim, Michitaka Honda, Chu Matsuda, Junichi Sakamoto
Publikováno v:
Annals of Oncology. 29:viii161